LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

被引:0
|
作者
Yang, Wei [1 ]
Burns, Colleen [1 ]
Lindquist, Kevin [2 ]
Dobkin, Julie [1 ]
Shin, Hee Rae [1 ]
Nguyen, Cindy [1 ]
Huang, Xiaodong [1 ]
Helms, Whitney [3 ]
Arce, Nicholas [2 ]
Mak, Yvonne [2 ]
Au, Audrey [1 ]
Abouzeid, Abraham [4 ]
Witek, Marta [4 ]
Leow, Ching Ching [1 ]
Gong, Xueqian [4 ]
Srinivasan, Mohan
Park, Joshua I. [2 ]
Driscoll, Kyla [1 ]
Hass, Andrew [4 ]
Holmgaard, Rikke [1 ]
Duramad, Omar [2 ]
Bedard, Kristin [2 ]
机构
[1] LoxoLilly, New York, NY USA
[2] LoxoLilly, South San Francisco, CA USA
[3] LoxoLilly, Silver Spring, MD USA
[4] Eli Lilly & Co, Indianapolis, IN USA
关键词
D O I
10.1182/blood-2024-200316
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:2785 / 2786
页数:2
相关论文
共 50 条
  • [31] T cell-dependent bispecific antibody anti-CD79b/CD3 as a potential therapy for B-cell malignancies
    Wang, Peiyin
    Hristopoulos, Maria
    Clark, Robyn
    Chen, Yvonne
    Ellerman, Diego
    Mathieu, Mary
    Spiess, Christoph
    Li, Jessica
    Chalouni, Cecile
    Sukumaran, Siddharth
    Stefanich, Eric
    Wallin, Jeffrey
    Li, Robert
    Zabka, Tanja
    Totpal, Klara
    Dennis, Mark
    Ebens, Allen
    Gould, Stephen
    Polson, Andrew
    Sun, Liping Laura
    CANCER RESEARCH, 2017, 77
  • [32] Target expression, preclinical activity and mechanism of action of EM801: a novel first-in-class IgG-based BCMA T-cell bispecific antibody for the treatment of multiple myeloma
    Seckinger, A.
    Delgado, J. A.
    Moreno, L.
    Neuber, B.
    Grab, A. L.
    Lipp, S.
    Merino, J.
    Vu, M. D.
    Strein, K.
    Prosper, F.
    Hundemer, M.
    San Miguel, J.
    Hose, D.
    Paiva, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 207 - 208
  • [33] The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
    Ruan, Dan-Yun
    Wei, Xiao-Li
    Liu, Fu-Rong
    Hu, Xi-Chun
    Zhang, Jian
    Ji, Dong-Mei
    Huang, Ding-Zhi
    Zhao, Yan-Qiu
    Pan, Hong-Min
    Liao, Wang-Jun
    Yang, Kun-Yu
    Xu, Nong
    Lu, Xiao-Xiao
    Chen, Yu-Ling
    Zhang, Wen
    Zhou, Hui
    Zhao, Hong-Yun
    Xu, Rui-Hua
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [34] Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
    Stadler, Christiane R.
    Baehr-Mahmud, Hayat
    Plum, Laura M.
    Schmoldt, Kathrin
    Koelsch, Anne C.
    Tuereci, Oelem
    Sahin, Ugur
    ONCOIMMUNOLOGY, 2016, 5 (03):
  • [35] Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma
    Gayle, Sophia
    Landrette, Sean
    Beeharry, Neil
    Conrad, Chris
    Hernandez, Marylens
    Beckett, Paul
    Ferguson, Shawn M.
    Mandelkern, Talya
    Zheng, Meiling
    Xu, Tian
    Rothberg, Jonathan
    Lichenstein, Henri
    BLOOD, 2017, 129 (13) : 1768 - 1778
  • [36] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
    Zhang, L.
    Ma, Y.
    Zhao, Y.
    Fang, W. F.
    Zhao, H.
    Huang, Y.
    Yang, Y.
    Hou, X.
    Wen, Z.
    Zhang, S.
    Wang, J.
    Xiao, S.
    Wang, H.
    Zhu, H.
    Olivo, M. S.
    Zhu, Y.
    ANNALS OF ONCOLOGY, 2023, 34
  • [37] Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
    Lu, Chia-Yen
    Chen, Gregory J.
    Tai, Pei-Han
    Yang, Yu-Chen
    Hsu, Yu-Shen
    Chang, Mingi
    Hsu, Chuan-Lung
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 473 (04) : 808 - 813
  • [38] Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies
    Gupta, Ira V.
    Jewell, Roxanne C.
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2011, 2012, 1263 : 43 - 56
  • [39] An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies
    Qi, Junpeng
    Chen, Shih-Shih
    Chiorazzi, Nicholas
    Rader, Christoph
    METHODS, 2019, 154 : 70 - 76
  • [40] Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas
    Philippar, Ulrike
    Lu, Tianbao
    Vloemans, Nele
    Bekkers, Mariette
    Van Nuffel, Luc
    Gaudiano, Marcello
    Wnuk-Lipinska, Katarzyna
    Van der Leede, Bas-jan
    Amssoms, Katie
    Kimpe, Kristof
    Medaer, Bart
    Greway, Tony
    Abraham, Yann
    Cummings, Max
    Trella, Emanuele
    Vanhoof, Greet
    Sun, Weimei
    Thuring, Jan Willem
    Connolly, Peter
    Linders, Jan
    Rui, Haopeng
    Balasubramanian, Sriram
    Johnson, Amy
    Gerecitano, John
    Goldberg, Jenna
    Edwards, James P.
    Elsayed, Yusri
    Smit, Jennifer
    Bussolari, Jaqueline
    Attar, Ricardo
    CANCER RESEARCH, 2020, 80 (16)